CR5278A - Formulacion oral de 2-metil-tieno-benzodiacepina - Google Patents

Formulacion oral de 2-metil-tieno-benzodiacepina

Info

Publication number
CR5278A
CR5278A CR5278A CR5278A CR5278A CR 5278 A CR5278 A CR 5278A CR 5278 A CR5278 A CR 5278A CR 5278 A CR5278 A CR 5278A CR 5278 A CR5278 A CR 5278A
Authority
CR
Costa Rica
Prior art keywords
oral formulation
benzodiacepine
theno
methyl
solid oral
Prior art date
Application number
CR5278A
Other languages
English (en)
Inventor
Randall Cochran George
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR5278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR5278A publication Critical patent/CR5278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una formulacion oral solida que comprende olanzapina como ingrediente activo,mezclada intimamente con un agente de cargaaglutinante,disgregante,un aglutinante seco para proporcionar friabilidad adecuada,y un lubricante,en la que dicha formulacion oral solida esta recubierta con un polimero seleccionado dentro del grupo formado por hidroxipropil hipromelosa, hidroxietil celulosa,hidroxidopropil celulosa entre otros.
CR5278A 1995-03-24 1996-03-12 Formulacion oral de 2-metil-tieno-benzodiacepina CR5278A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
CR5278A true CR5278A (es) 1996-07-04

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
CR5278A CR5278A (es) 1995-03-24 1996-03-12 Formulacion oral de 2-metil-tieno-benzodiacepina

Country Status (46)

Country Link
US (4) US5919485A (es)
EP (2) EP1093815B1 (es)
JP (1) JPH11502848A (es)
KR (1) KR100408172B1 (es)
CN (1) CN1178662C (es)
AP (1) AP679A (es)
AR (2) AR002720A1 (es)
AT (3) ATE284695T1 (es)
AU (1) AU696601B2 (es)
BG (1) BG62594B1 (es)
BR (1) BR9607791A (es)
CA (1) CA2216372C (es)
CH (1) CH691217A5 (es)
CO (1) CO4700474A1 (es)
CR (1) CR5278A (es)
CZ (1) CZ296007B6 (es)
DE (3) DE69615887T2 (es)
DK (3) DK0733367T3 (es)
EA (1) EA000938B1 (es)
EE (1) EE03551B1 (es)
EG (1) EG24077A (es)
ES (2) ES2232379T3 (es)
FI (1) FI973749L (es)
GB (1) GB2313783B (es)
HU (1) HU225269B1 (es)
IL (1) IL117611A (es)
IS (1) IS1903B (es)
LT (1) LT4350B (es)
LU (1) LU90115B1 (es)
LV (1) LV11983B (es)
MY (1) MY113440A (es)
NO (1) NO320388B1 (es)
NZ (1) NZ306111A (es)
OA (1) OA10511A (es)
PE (1) PE44997A1 (es)
PL (1) PL188316B1 (es)
PT (2) PT733367E (es)
RO (1) RO118370B1 (es)
SE (1) SE9703206D0 (es)
SI (3) SI9620041A (es)
SK (1) SK283745B6 (es)
TR (1) TR199701018T1 (es)
TW (1) TW426526B (es)
UA (1) UA44766C2 (es)
WO (1) WO1996029995A1 (es)
ZA (1) ZA962338B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
PT1246827E (pt) * 1999-12-28 2005-08-31 Cipla Ltd Novas formas polimerficas da olanzapina
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
US20050112196A1 (en) * 2003-10-07 2005-05-26 Jianbo Xie Rapidly disintegrating formulation
JP2007511605A (ja) * 2003-11-18 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オランザピン含有経皮薬物送達組成物
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20060240101A1 (en) * 2005-04-22 2006-10-26 Shubha Chungi Orally disintegrating pharmaceutical tablet formulations of olanzapine
EP2261323A1 (en) * 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
JP4938006B2 (ja) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CN101484141A (zh) * 2006-07-05 2009-07-15 比利姆制药工业和贸易公司 包含抗氧化剂的稳定的奥氮平制剂
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
CN101983055B (zh) * 2008-01-31 2013-05-08 杏林制药株式会社 以咪达那新为有效成分的口腔内速崩片的制造方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
AU2010229821A1 (en) * 2009-03-25 2011-11-17 Caitin, Inc. Supersonic cooling system
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
CN117085022A (zh) * 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
AT405606B (de) 1999-10-25
ATE206924T1 (de) 2001-11-15
AR001405A1 (es) 1997-10-22
US6190698B1 (en) 2001-02-20
DE69634053D1 (de) 2005-01-20
FI973749A0 (fi) 1997-09-22
LV11983A (lv) 1998-03-20
AR002720A1 (es) 1998-04-29
CZ300197A3 (en) 1997-12-17
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
CN1178662C (zh) 2004-12-08
OA10511A (en) 2002-04-24
WO1996029995A1 (en) 1996-10-03
BR9607791A (pt) 1998-07-07
US20010018071A1 (en) 2001-08-30
MY113440A (en) 2002-02-28
IS4565A (is) 1997-09-22
NO974363L (no) 1997-11-17
US20050085462A1 (en) 2005-04-21
LU90115B1 (fr) 1997-09-10
US5919485A (en) 1999-07-06
HU225269B1 (en) 2006-08-28
DE69634053T2 (de) 2005-12-22
EE9700328A (et) 1998-06-15
EE03551B1 (et) 2001-12-17
TW426526B (en) 2001-03-21
IL117611A0 (en) 1996-07-23
EP1093815B1 (en) 2004-12-15
PE44997A1 (es) 1997-10-23
UA44766C2 (uk) 2002-03-15
RO118370B1 (ro) 2003-05-30
FI973749A7 (fi) 1997-09-22
SE9703206L (sv) 1997-09-05
EA199700260A1 (ru) 1998-02-26
ES2164837T3 (es) 2002-03-01
BG101901A (bg) 1998-10-30
PL188316B1 (pl) 2005-01-31
DE19681287T1 (de) 1998-03-19
DE69615887T2 (de) 2002-04-11
CN1179102A (zh) 1998-04-15
SE9703206D0 (sv) 1997-09-05
KR19980703189A (ko) 1998-10-15
DK0733367T3 (da) 2001-11-26
NO320388B1 (no) 2005-11-28
EG24077A (en) 2008-05-11
NZ306111A (en) 1999-02-25
IS1903B (is) 2003-11-20
GB2313783B (en) 1998-11-18
JPH11502848A (ja) 1999-03-09
PT733367E (pt) 2002-03-28
SI1093815T1 (en) 2005-06-30
DK173323B1 (da) 2000-07-24
GB2313783A (en) 1997-12-10
EA000938B1 (ru) 2000-06-26
LV11983B (en) 1998-07-20
SI9620041A (sl) 1998-06-30
DK1093815T3 (da) 2005-04-25
US6780433B2 (en) 2004-08-24
EP1093815A1 (en) 2001-04-25
ATA902296A (de) 1999-02-15
BG62594B1 (bg) 2000-03-31
LT97149A (lt) 1998-01-26
SI0733367T1 (en) 2002-06-30
DE69615887D1 (de) 2001-11-22
PT1093815E (pt) 2005-03-31
HUP9800410A3 (en) 2000-01-28
CZ296007B6 (cs) 2005-12-14
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
AU696601B2 (en) 1998-09-17
GB9719817D0 (en) 1997-11-19
US7229643B2 (en) 2007-06-12
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
HUP9800410A2 (hu) 1998-07-28
CH691217A5 (de) 2001-05-31
TR199701018T1 (xx) 1998-01-21
LT4350B (lt) 1998-05-25
AP9701064A0 (en) 1997-10-31
IL117611A (en) 2002-05-23
EP0733367B1 (en) 2001-10-17
AP679A (en) 1998-09-28
CO4700474A1 (es) 1998-12-29
NO974363D0 (no) 1997-09-22
CA2216372A1 (en) 1996-10-03
CA2216372C (en) 2007-11-20
ZA962338B (en) 1997-09-22
MX9707186A (es) 1997-11-29
AU5428096A (en) 1996-10-16
FI973749L (fi) 1997-09-22
DK109097A (da) 1997-11-12
ES2232379T3 (es) 2005-06-01

Similar Documents

Publication Publication Date Title
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
DE69919863T8 (de) Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2180574T3 (es) Formulaciones de liberacion controlada de oxibutinina.
BR9507164A (pt) Composiçao farmacêutica em forma de gel para o tratamento de distúrbios da pele processo de tratamento de pele e uso de uma combinaçao de um agente gelificante de polimero e um alcanol inferior de etil hidroxietil celulose e de um alcanol inferior
ES2101082T3 (es) Composiciones de liberacion controlada.
EE05022B1 (et) Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
ES2145557T3 (es) Composiciones de ablandamiento del agua y composiciones detergentes.
AR003908A1 (es) Tableta de liberacion controlada
CO5070580A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
AR021471A1 (es) Una composicion termoplastica y la fibra preparada con dicha composicion
ES2159591T3 (es) Composicion de liberacion controlada.
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
AR007582A1 (es) Composicion para el lavado de la piel, procedimiento para prepararla y el uso de la misma para la fabricacion de medicamentos dado el caso, para eltratamiento cosmetico de la piel.
DE69024363D1 (de) Erodierbare makroporöse hydrogelpartikeln sowie deren herstellung
AR010716A1 (es) Formulacion para tabletas efervecentes desinfectantes y metodo para formar una solucion desinfectante
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
ES2193595T3 (es) Agentes para el tratamiento de fibras de queratina.
BR0009927B1 (pt) mÉtodo para produzir uma matriz de liberaÇço controlada, amàrfica ou parcialmente amàrfica insolével em Água.
ATE300606T1 (de) Waschmittelformkörper mit verbesserten auflöseeigenschaften

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)